<DOC>
	<DOCNO>NCT00222027</DOCNO>
	<brief_summary>Several prognostic predictor , include baseline ALL feature response initial therapy , describe adult ALL raise issue whether predictor might redundant must consider treatment stratification . In GRAALL-2003 prospective Phase 2 study , aim hierarchize following high-risk factor Ph-negative ALL patient .</brief_summary>
	<brief_title>Feasibility Risk-Adapted Therapy Young Adult Acute Lymphoblastic Leukemia : Multicenter Trial</brief_title>
	<detailed_description>1 ) baseline ( BL ) : WBC30G/L B-lineage , CNS involvement , MLL-AF4 E2A-PBX fusion , haploidy/near-triploidy ; 2 ) early response ( ER ) : corticoresistance prophase ( CsR ) , chemoresistance Day 8 ( ChR ) ; CsR and/or ChR patient plan receive high dos cyclophosphamide ( HyperC ) Day 15 induction ; 3 ) induction response ( IR ) : CR Ig-TCR minimal residual disease ( MRD ) 10-2 standard HyperC induction . Allogeneic stem cell transplantation propose patient donor least one BL , ER , IR factor .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1559 year acute lymphoblastic leukemia newly diagnose sign write informed consent Lymphoblastic lymphoma Acute lymphoblastic leukemia 3 Chronic Myeloid Leukemia acutisation Sever organ condition</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>adult patient</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>Young adult patient</keyword>
</DOC>